Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: checkmatepharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/6/2021 | $7.00 | Neutral → Buy | B of A Securities |
B of A Securities upgraded Checkmate Pharmaceuticals from Neutral to Buy and set a new price target of $7.00
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. "I am very pleased to welcome Alan Bash as President and CEO. With ove
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors ("Board"). "Joy's impressive track record in immuno-oncology focused clinical development will be valuable as we continue to advance vidutolimod toward registration in melanoma and proof of concept in additional indications," commented Alan Fuhrman, Interim CEO and President of Checkmate. "We are pleased to welcome Joy to Checkmate's Board." Dr. Yan
Robert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Robert F. Dolski as Chief Financial Officer. Mr. Dolski brings to Checkmate more than 20 years of diversified management experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies. In addition to Mr
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update. "We remain focused on the execution of the clinical program for vidutolimod and are delighted with the opportunity to become part of Regeneron, who will help to accelerate the development of vidutolimod as a potential novel treatment for multiple tumor types," said Alan Bash, President and Chief Executive Officer of Checkmate. "This is an excitin
Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) a clinical stage biopharmaceutical company focused on proprietary t
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of biomarker signature data from two studies evaluating vidutolimod, a first-in-class, immunostimulatory, noninfectious virus-like particle (VLP) containing a CpG-A Toll-like receptor 9 (TLR9) agonist. The first study evaluated vidutolimod in patients with advanced anti-PD-(L)1 refractory melanoma who received intratumoral vidutolimod monotherapy or in combination with intravenous pembrolizumab, and
Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing initiated in cohorts for PD-1 refractory non-melanoma skin cancers Preliminary clinical data readouts anticipated in second half of 2022 CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced full year 2021 financial results and provided a business update. "Our vidutolimod p
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present biomarker data at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, Louisiana from April 8-13, 2022. An e-poster will be made available online starting Friday, April 8 at 1:00pm ET. Poster Presentation Details: Title: Novel transcriptional signatures associated with antitumor activity in vidutolimod (vidu)-treated patients (pts) with anti-PD-
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. "I am very pleased to welcome Alan Bash as President and CEO. With ove
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors ("Board"). "Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios," said Alan Fuhrman, Interim CEO and President of Checkmate. "We are thrilled to strengthen Checkmate's Board by leveraging Jon's broad experience across academia,
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022. The pre-recorded webcast will be available on-demand starting on Monday, January 10 at 7:00am ET. Checkmate will also host 1x1 investor meetings during the conference. About Checkmate Pharmaceuticals Checkmate Pharmaceuticals is a clinical stage biotechnology company
SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13D - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13G - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC 13G - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
15-12B - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
EFFECT - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
25-NSE - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
POS AM - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
8-K - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
SC 14D9/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
SC TO-T/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)